• Prescribing Information
  • PATIENT SITE
DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) logo
DARZALEX FASPRO® DOSING & ADMINISTRATION GUIDE
DARZALEX® DOSING & ADMINISTRATION GUIDE
GET IN TOUCH
PRODUCT USE
INDICATIONS AND DOSING
  • Newly Diagnosed
    • DVRd
    • DRd
    • DVMP
    • DVTd
  • Relapsed or Refractory
    • DRd
    • DPd
    • DKd
    • DVd
    • Monotherapy
  • NCCN RECOMMENDATIONS
  • ADMINISTRATION
  • FRONTLINE DVRd
  • PATIENT PROFILE
  • PERSEUS STUDY
  • PROVEN EFFICACY
  • DEMONSTRATED SAFETY
  • FRONTLINE DRd
  • PATIENT TYPES
  • PROVEN EFFICACY
  • DEMONSTRATED SAFETY
  • HIGH-RISK SUBGROUP
  • FRAILTY SUBGROUP
  • AGE SUBGROUP
  • CONTINUING DRd TREATMENT
  • MAINTAINING TREATMENT BENEFITS
  • TIME TO DEEPEST RESPONSE
  • SAFETY OVER TIME
  • ADVANCING PATIENT CARE
  • RESOURCES
  • PRACTICE SUPPORT
  • PATIENT SUPPORT
  • MECHANISM OF ACTION
  • GET IN TOUCH
  • Q&A
  • FOR APPs & NURSES
    • PRESCRIBING INFORMATION
      • DARZALEX FASPRO® Prescribing Information
      • DARZALEX FASPRO® la información de prescripción
      • DARZALEX® Prescribing Information
    • Important Safety Information
      • DARZALEX FASPRO® Important Safety Information
      • DARZALEX® Important Safety Information
    • Contact Us
      • 1-833-565-9631
      • Email Medical Information Center
      • SEARCH J&J MEDICAL CONNECT
      • CONTACT US
    • Dosing & Administration Guide
      • DARZALEX FASPRO® Dosing & Administration Guide
      • DARZALEX® Dosing & Administration Guide
    • PATIENT SITE
    • MM Portfolio
    • This site is intended for
      US healthcare professionals.

    Choose DARZALEX FASPRO® to treat newly diagnosed patients with multiple myeloma, regardless of transplant status

    Site Map

    1. Home
    2. Site Map
    • Product Use
      • Indications and Dosing
        • Newly Diagnosed
          • DVRd
          • DRd
          • DVMP
          • DVTd
        • Relapsed or Refractory
          • DRd
          • DPd
          • DKd
          • DVd
          • Monotherapy
      • NCCN Recommendations
      • Administration
    • Frontline DVRd
      • Patient Profile
      • PERSEUS Study
      • Proven Efficacy
      • Demonstrated Safety
    • Frontline DRd
      • Patient Types
      • Proven Efficacy
      • Demonstrated Safety
      • High-Risk Subgroup
      • Frailty Subgroup
      • Age Subgroup
    • Continuing DRd treatment
      • Maintaining Treatment Benefits
      • Time to Deepest Response
      • Safety Over Time
      • Advancing Patient Care
    • Resources
      • Practice Support
      • Patient Support
      • Mechanism of Action
      • Get in Touch
      • Q&A
    • For APPs and Nurses
    • Medical Information Center
    • Site Map